• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Reuters tracks down mystery Olympus banker in Hong Kong

Reuters tracks down mystery Olympus banker in Hong Kong

November 28, 2011 By MassDevice staff

Olympus

Akio Nakagawa, a key figure from Olympus Corp.’s (TYO:7733) acquisition fee scandal was found in Hong Kong yesterday by the Reuters news agency.

The Japanese banker, whose company received an unprecedented $687 million payout during the Tokyo-based technology giant’s $2.2 billion acquisition of the Gyrus Group in 2008, was found living in a luxury high-rise near Hong Kong’s financial district.

Nakagawa, a former PaineWebber banker, refused to answer any questions about the financial scandal, according to the news agency.

Sign up to get our free newsletters delivered straight to your inbox

Former Olympus CEO Michael Woodford broke the story in October with claims that he was terminated just two weeks after taking the corner office for commissioning a PricewaterhouseCoopers investigation that uncovered abnormally steep advisory fees related to the Gyrus deal.

Most of the payments went to a pair of mysterious entities called AXES and AXAM. The PwC report identified former Wall Street banker Hajime "Jim" Sagaway as the lead for AXES and the director of AXAM, which is a tax haven incorporated in the Cayman Islands.

Woodford also questioned three other 2008 acquisitions that cost a total of $773 million and were written down by 75 percent that year. He submitted a report to Olympus senior management Oct. 13, including a call for the resignation of several members of the management team, according to an Olympus press release.

Olympus admitted to channeling nearly $1.5 billion in possibly illegal payments to conceal heavy losses on investments over the last two decades.

Regulators in the U.S. and Japan are investigating allegations that Olympus channeled more than $1.5 billion through offshore funds after suspicions were aroused by Woodford, according to Bloomberg BusinessWeek.

Olympus shares have lost more than 60 percent since Woodford’s mid-October termination, falling from a closing price of roughly $31.91 (¥2,482) Friday, Oct. 13, to about $12.75 (¥990) in mid-morning trading today.

Filed Under: Legal News, Mergers & Acquisitions, News Well, Wall Street Beat Tagged With: Olympus

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy